Mediwound to present phase 2 escharex® data at the symposium on advanced wound care (sawc) spring 2023

Data to be highlighted in oral and poster presentations yavne, israel, april 26, 2023 (globe newswire) -- mediwound ltd. (nasdaq: mdwd), a fully-integrated biopharmaceutical company focused on next-generation enzymatic solutions for tissue repair, today announced the company will present updated clinical data from the three escharex® phase 2 trials at the 2023 symposium on advanced wound care (sawc) spring | wound healing society taking place in national harbor, maryland on april 26-30, 2023.
MDWD Ratings Summary
MDWD Quant Ranking